PGD No Administration of Human Papillomavirus Vaccine (HPV) Types 6, 11, 16 and 18 - Gardasil - September 2012
|
|
- Berenice Cross
- 5 years ago
- Views:
Transcription
1 Notice to all staff: NHS Hertfordshire Patient Group Directions (PGDs) may only be used by members of the healthcare professions named on the title page and only if each professional has individually been listed by their manager as an authorised user meeting the competency and training requirements of that PGD. Each healthcare professional using a PGD must also have signed a copy of that PGD and have one available to refer to. Staff must not download PGDs from the intranet and use them. The PGDs are only on the intranet so that clinical managers can access them when they need to authorise their team members or to check that their team is using the most recent version. Managers should also have signed the appropriate section of the PGD. Valid from: 1 st September 2012 Expiry date: 1 st September
2 PGD Number Administration of Human Papillomavirus Vaccine (HPV) Types 6, 11, 16 and 18 - Gardasil by registered nurses employed by NHS Hertfordshire or Hertfordshire GP Practices and signatories to the PGD This Patient Group Direction has been approved on behalf of NHS Hertfordshire by: Clinical Standards Committee Authorising Officer for NHS Signature: Hertfordshire Date: 1 st August 2012 Date of Issue September 2012 Issue Number PGD Date of Review September 2014 NHS Hertfordshire is committed to being an organisation within which diversity, equality and human rights are valued. We will not discriminate either directly or indirectly and will not tolerate harassment or victimisation in relation to gender, marital status (including civil partnerships), gender reassignment, disability, race, age, sexual orientation, religion or belief, trade union membership, status as a fixed-term or part-time worker, socio-economic status and pregnancy or maternity leave status Equality Impact Assessment (Level 1) undertaken by the author Date: April 2012 This document is available electronically or in a larger font or alternative format on request. Valid from: 1 st September 2012 Expiry date: 1 st September
3 Document History Progress Lead Person & Contact Date Number V1 First draft Jo Jenkins May 2012 V2 First revised draft Jo Jenkins May 2012 V3 Final draft Including CSC amendments July 2012 Circulation List Heather Gray Lead May 2012 Pharmacist NHS Hertfordshire Dr Mike Edwards NHS Hertfordshire Medical Director Heather Moulder, NHS Hertfordshire Executive Nurse Approved and ratified by 18 th July 2012 CSC Review Date September 2014 Date of Archiving PGD September 2012 Table of Contents Page Front Sheet 3 Clinical Condition or Situation to which the Direction Applies 4 Description of Treatment 5 Adrenaline management in the event of an anaphylactic reaction 7 Audit 7 Characteristics and qualification required of staff 8 References 8 Management/authorisation of Patient Group Direction 9 Valid from: 1 st September 2012 Expiry date: 1 st September
4 PGD Number Administration of Human Papillomavirus Vaccine (HPV) Types 6, 11, 16 and 18 - Gardasil by registered nurses employed by NHS Hertfordshire or Hertfordshire GP Practices and signatories to the PGD Valid from: 1 st September 2012 Expiry (review) date: 1 st September 2014 After this date the direction is no longer valid. (Note: a review will be carried out sooner as a result of any new safety information.) Supersedes: No previous PGD for Gardasil Development of Patient Group Direction This Patient Group Direction has been developed on behalf of HCT by: Name Signature Date NHS Hertfordshire Medical Director Dr Mike Edwards 18 th July 2012 NHS Hertfordshire Executive Nurse Heather Moulder 17 th May 2012 HCT Pharmacist Jo Jenkins 16 th May 2012 Valid from: 1 st September 2012 Expiry date: 1 st September
5 1. Clinical condition or situation to which the direction applies Indication Active immunisation against invasive cervical cancer caused by human papillomavirus (HPV) types 6, 11, 16 and 18. Criteria for inclusion Informed consent obtained and documented All girls aged 12 to 13 years (in school year 8), as a primary course of immunisation against human papillomavirus (HPV) types 6,11,16 and 18 as per the National Immunisation Schedule Where a female in the target cohort (aged over 12 and less than 18 years) presents with an inadequate vaccination history, every effort should be made to clarify what doses they have had. A female (aged over 12 years and under 18 years) who has not completed the schedule should complete the vaccination course at the minimum interval where possible. Females coming to the UK from overseas may not have been offered protection against HPV in their country of origin and should be offered vaccination where appropriate. If a course has begun with Gardasil then the course should be completed with Gardasil. If a course has been started with Cervarix the course should be completed with this see the Cervarix PGD. Criteria for exclusion There are very few individuals who cannot receive HPV vaccine. When there is doubt, appropriate advice should be sought from a GP rather than withholding the vaccine. Cautions/Need for further advice from a doctor Consent refused Girls under the age of 12 years Girls who have commenced their HPV vaccination course during academic year with Cervarix see PGD 15 Severe febrile illness - postpone. Minor infections without fever or systemic upset are not reasons to postpone immunisation A confirmed anaphylactic reaction to a previous dose of a HPV vaccine A confirmed anaphylactic reaction to any component of the vaccine Pregnancy Gardasil may be given at the same time as other vaccines, but at a different injection site, preferably different limbs. If given in the same limb, it should be given at least 2.5cm apart. Ideally the same vaccine should be used for the whole primary course as there is currently no evidence on the interchangeability of the two HPV vaccine products. In patients with endogenous or iatrogenic immunosuppression including HIV, the HPV vaccine can be given but the response may be lower and further doses may be required seek advice from GP. Where possible HPV vaccine should be administered at least 2 weeks before starting immunosuppressive treatment. Valid from: 1 st September 2012 Expiry date: 1 st September
6 Action if excluded Record in the patient s medical notes Specialist advice must be sought on the vaccines and circumstances under which they should be given. The risk to the individual of not being immunised must be taken into account. Action if patient Give advice about protective effects of the vaccine and declines treatment the risks of infection and disease complications. Document advice given. Inform or refer to GP as appropriate. 2. Description of Treatment Name, strength and Gardasil human papillomavirus vaccine (HPV) types 6, 11, formulation of drug 16 and 18 (recombinant, adjuvanted, adsorbed) bivalent suspension for injection - pre-filled 0.5ml syringe Legal status POM (prescription only medicine) Black triangle Method / Route Shake gently; agitate immediately before use to obtain uniform suspension. Intramuscular injection (deltoid area of the upper arm is the recommended site) The deep subcutaneous route may be used for patients with thrombocytopenia or individuals at risk of haemorrhage Attach the needle by twisting in a clockwise direction until the needle fits securely on the syringe. If 2 needles of different lengths are provided in the pack, choose the appropriate needle to ensure an IM administration depending on your patient's size and weight. Gardasil must not be administered either intravascularly or intradermally. Dose / Dose range Frequency of administration 0.5ml dose Primary course of three doses given at 0, 1 to 2 months and 6 months The second dose should be administered one to two months after the first dose and the third dose at least 6 months after the first dose All 3 doses should be given within a 12 month period. If the course is interrupted, it should be resumed but not repeated, ideally allowing the appropriate interval between the remaining doses. Duration Patient advice / Follow up treatment In cases where the second dose of HPV vaccine is given late, the minimum interval between the second and third dose of Gardasil is 3 months. See above Provide suitable printed Patient Information Leaflet (PIL) as supplied with the vaccine or available via Where appropriate patient to remain on the premises for minutes following immunisation (i.e. if unlikely to be supervised within this time) Valid from: 1 st September 2012 Expiry date: 1 st September
7 Give advice on the management of post-immunisation pyrexia Give advice on possible side effects and their management sore arm is a normal reaction to the injection Inform patient where applicable when subsequent doses are due. Advise that vaccination is not a substitute for routine cervical screening Adverse Reactions and Appropriate medical equipment and drugs for the treatment their Management of an anaphylactic event to be available (see local anaphylaxis guidelines or the current edition of the British National Formulary (BNF) Local reaction at injection site see GP if severe (see product s Summary of Product Characteristics (SPC)) Consult GP if fever > 39.5 C, or other serious symptoms Very common ( 1/10) o Headache o At the injection site: erythema, pain, swelling o Common ( 1/100 to <1/10) o Pyrexia (fever over 38 C) o At the injection site: hematoma, pruritis o Pain in extremity o Nausea Rare ( 1/10,000 to <1/1,000) o Urticaria Very rare (<1/10,000) o Bronchospasm Other adverse effect (unknown frequency of occurrence) o Injection-site cellulitis o Asthenia o Chills o Fatigue o Malaise o Arthralgia o Myalgia o Vomiting o Dizziness o Guillain-Barré syndrome Reporting procedure of Adverse Reactions o o Syncope sometimes accompanied by tonic-clonic movements Hypersensitivity reactions including anaphylactic/anaphylactoid reactions Idiopathic thrombocytopenic purpura o Lymphadenopathy o Injection-site cellulitis See product s SPC or the Immunisation against Infectious Disease Green Book for full/further details. Initially via GP and documented in the patient s medical notes Complete an incident form All suspected adverse reactions to be reported to the Commission of Human Medicines (yellow card by the GP or Nurse who manages the anaphylaxis situation. State brand and batch number. Valid from: 1 st September 2012 Expiry date: 1 st September
8 Black triangle medication all adverse reactions (even if just suspected or minor) must be reported via the Yellow Card scheme. Drug Interactions None reported Additional Facilities Immediate access to epinephrine (adrenaline) 1 in 1000 injection Special Considerations Do not mix HPV vaccine with any other vaccines / Additional Information Arrangements for Store vaccine at 2 C to 8 C (in a refrigerator). Do not handling, security, freeze. Protect from light. storage and labelling If the vaccine has been frozen the vaccine must be discarded. Shake well before use All medicines supplied to a patient under a PGD must comply with the European Commission (EC) labelling and leaflet directive i.e. must be fully labelled and an appropriate Patient Information Leaflet (PIL) supplied. For administration of vaccines a PIL should be offered or made available to the patient to read. Records The following information should be recorded accurately: vaccine name, product name, batch number and expiry date site(s) used including, clear description of which injection was administered in each site, especially where two injections were administered in the same limb date immunisation(s) were given dose administered name and signature of vaccinator. advice given to patient detail of any adverse reaction and action taken This information should be recorded in: patient-held record or Personal Child Health Record (PCHR, the Red Book) for children patient s GP record or other patient record, depending on location Child Health Information System Practice computer system 3. Adrenaline (Epinephrine) Management in the Event of an Anaphylactic Reaction Adrenaline (epinephrine) 1:1000 (1mg/ml) Intramuscular injection Subcutaneous route (not generally recommended) Age of Patient Volume of adrenaline (epinephrine) 1:1000 (1mg/1ml) 6 12 years 0.3ml (300 micrograms) Adults and adolescents over 12 years 0.5ml (500 micrograms) (0.3ml (300 micrograms) if the child is small or pre-pubertal) Valid from: 1 st September 2012 Expiry date: 1 st September
9 These doses may be repeated if necessary at 5 minute intervals according to blood pressure, pulse and respiratory function with urgency of hospital transfer * Use suitable syringe for measuring small volumes 4. Audit Stock Reconciliation Stock Storage Stock balances should be reconcilable with receipts, administration records and disposals on an individual patient basis. Product should be stored in accordance with the specifications of the PGD and Summary of Product Characteristics relating to the vaccine 5. Characteristics of Staff Qualifications required Registered nurse with current Nursing & Midwifery Council (NMC) registration employed by NHS Hertfordshire Additional requirements Has undertaken appropriate training for working under PGDs for supply and administration of medicines Evidenced competency to undertake immunisations Evidenced up to date training in Cardiopulmonary Resuscitation skills (annually) and management of anaphylaxis (yearly) in line with NHS Hertfordshire s Mandatory Training Needs Framework Continued training requirements Attend training dates as required and keep up to date with changes The Registered Nurse must act at all times in accordance with the Nursing and Midwifery Council (NMC) code of professional conduct and Standards for the Administration of Medicines, and must at all times acknowledge any limitations in their knowledge or competence. 6. References - National / Local Policies or Guidelines 1. Department of Health (2006) Immunisation against infectious disease (HMSO). Updated at Accessed 2 nd April Current edition of the British National Formulary (BNF) Accessed 2 nd April Most recent version of the Manufacturer s Summary of Product Characteristics (SPC) available at Accessed 2 nd April Immunisation website Accessed 2 nd April Health Service Circular HSC 2000/026: Patient Group Directions (England only), 9 August Department of Health, CMO letters 7. NMC Standards for Medicines Management (2007) 8. NMC Code of Professional Conduct (2008) 9. Resuscitation Council (UK) Emergency Medical treatment of Anaphylactic Reactions by first medical responders and Community Nurses (updated January 2008) 10. Department of Health (6 th April 2001) Reference Guide to Consent for Examination or Treatment. Crown copyright. ( 11. Introduction of Human Papillomavirus vaccine into the National immunisation Programme CMO letters dated 2 nd May 2008, 15 th May 2008 & 19 th June HPV immunisation programme change of supply to Gardasil from September 2012 Letter from the DoH Director of Immunisations 25 th November 2011 Valid from: 1 st September 2012 Expiry date: 1 st September
10 7. Management of Patient Group Direction number Authorisation of GP/Clinical Lead for the administration of the named vaccine without a prescription by the named nurse(s) below I,. (name and designation), confirm that the named nurse(s) who has/have signed this Patient Group Direction to administer the above vaccine is/are competent to operate under the PGD and fulfil the criteria set out in the Characteristics of Staff section. I give authorisation for the named nurse(s) who has/have signed this Patient Group Direction to administer the above named preparation as described in this direction and in accordance with this PGD. Signed Date Practice Address: This Patient Group Direction is to be read, agreed to and signed by all registered nurses it applies to. One copy should be given to each nurse with the original signed copy being easily accessible within the practice/clinical setting. Once fully signed a copy of this page only to be retained by the GP. By completing the section below I confirm that I have read and understood the content of this Patient Group Direction and that I fulfil the criteria set out in the Characteristics of Staff section and I am willing, competent and authorised to work under it within my professional code of conduct. Name and designation of Authorised Nurse Signature of Authorised Nurse Date Valid from: 1 st September 2012 Expiry date: 1 st September
by registered nurses employed by NHS Hertfordshire or Hertfordshire GP Practices and signatories to the PGD
Notice to all staff: NHS Hertfordshire Patient Group Directions (PGDs) may only be used by members of the healthcare professions named on the title page and only if each professional has individually been
More informationPatient Group Direction (PGD) Number :
Notice to all staff: The Patient Group Directions (PGDs) for the Hertfordshire and South Midlands Area Team may only be used by members of the healthcare professions named on the title page, and only if
More informationPatient Group Direction (PGD) Number (minor amendment June 2014):
Notice to all staff: The Patient Group Directions (PGDs) for the Hertfordshire and South Midlands Area Team may only be used by members of the healthcare professions named on the title page, and only if
More informationPatient Group Direction (PGD) Number :
Notice to all staff: The Patient Group Directions (PGDs) for the Central Midlands Area may only be used by members of the healthcare professions named on the title page, and only if each professional has
More informationPatient Group Direction (PGD) Number :
Notice to all staff: The Patient Group Directions (PGDs) for the Hertfordshire and South Midlands Area Team may only be used by members of the healthcare professions named on the title page, and only if
More informationDocument Details Patient Group Direction Hepatitis A vaccine (Havrix Monodose ) Trust Ref No Local Ref (optional) Main points the
Document Details Title Patient Group Direction Hepatitis A vaccine (Havrix Monodose ) Trust Ref No 1506-41174 Local Ref (optional) Main points the Active immunisation against infection caused by Hepatitis
More informationDocument Details. Patient Group Direction
Document Details Title Patient Group Direction (PGD) Hepatitis B Vaccine (Engerix ) Trust Ref No 1505-41182 Local Ref (optional) Main points the Immunisation against Hepatitis B document covers Who is
More informationSAMPLE. PGD Reviewed by: Chris Faldon, John Maloney, Tim Patterson, Adrian MacKenzie, Claire Stein
Patient Group Direction for the supply or administration of haemophilus influenzae type B and meningococcal conjugate vaccine to children requiring immunisation as part of the national childhood vaccination
More informationThis document expires on Patient Group Direction No. VI 5
Patient Group Direction (PGD) for The Administration of Combined Adsorbed Diphtheria, Tetanus, Pertussis, (Acellular Component) and Inactivated Poliomyelitis Vaccine (Infanrix-IPV ) to children aged between
More informationThis document expires on Patient Group Direction No. VI 7
Patient Group Direction (PGD) for The Administration of Combined low-dose Diphtheria, Tetanus, and Inactivated Polio Vaccine (Revaxis ) to individuals aged over 10 years, by Registered Nurses employed
More informationSAMPLE. PGD reviewed by: Dr Tim Patterson, Chris Faldon, John Maloney, Adrian Mackenzie
Patient Group Direction for the Supply or Administration of combined Diphtheria, Tetanus, acellular Pertussis, inactivated Polio vaccine and Haemophilus type b conjugate Vaccine (Infanrix-IPV-HIB) to children
More informationPatient Group Direction (PGD) Number :
Notice to all staff: The Patient Group Directions (PGDs) for the Hertfordshire and South Midlands Area Team may only be used by members of the healthcare professions named on the title page, and only if
More informationThis document expires on Patient Group Direction No. VI 11
Patient Group Direction (PGD) for The Administration of Combined Inactivated Hepatitis A & Hepatitis B Vaccine (Twinrix adult, Twinrix paediatric) to Adults and Children over one year by Registered Nurses
More informationThis document expires on Patient Group Direction Number VI 19
Patient Group Direction (PGD) for The Administration of Pneumococcal Polysaccharide Vaccine (PPV, Pneumovax II ) to adults over 65 years and at risk groups aged 2 years and over, by Registered Nurses employed
More informationGG&C PGD ref no: 2016/1338 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2016/1338 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: For active immunisation of individuals
More informationPROCEDURE REF NO SABP/EXECUTIVE BOARD/0017
PROCEDURE REF NO SABP/EXECUTIVE BOARD/0017 NAME OF PROCEDURE: Medicines Procedure: Patient Group Directions for the Administration of Hepatitis B Vaccine for SABP Drug and Alcohol Teams. PURPOSE OF PROCEDURE:
More informationGG&C PGD ref no: 2016/1408 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2016/1408 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Active immunisation against disease
More informationCommunity Psychiatric Nurse. Consultant Psychiatrist, Substance Misuse Services
PATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF HEPATITIS A VACCINE (HAVRIX MONODOSE VACCINE) BY REGISTERED NURSES WORKING IN THE COMMUNITY SUBSTANCE MISUSE TEAMS Version Number : 2 Patient Group
More informationPatient Group Direction For The Administration Of H1N1 (Swine Flu) vaccine
n Patient Group Direction For The Administration Of H1N1 (Swine Flu) vaccine October 2009 PGD version template-2009.1 Page 1 of 8 Rationale Patient Group Direction For The Administration Of H1N1 (Swine
More informationPATIENT GROUP DIRECTION. Oral (live attenuated) Typhoid Vaccine (Ty21a) (Vivotif )
PATIENT GROUP DIRECTION Administration of: Oral (live attenuated) Typhoid Vaccine (Ty21a) (Vivotif ) By: Practice Nurses In: General Practice It is the responsibility of the professional working under
More informationClinical Condition Indication:
GG&C PGD ref no: 2012/943 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: For active immunisation of individuals
More informationPatient Group Direction For the supply and administration of
Patient Group Direction For the supply and administration of COMBINED HEPATITIS A AND HEPATITIS B VACCINE TWINRIX PAEDIATRIC For Children aged 1 year to under 16 years TWINRIX ADULT For Adults and Adolescents
More informationPatient Group Direction For the supply and administration of
Patient Group Direction For the supply and administration of Adsorbed low dose DIPHTHERIA/TETANUS/acellular PERTUSSIS/ inactivated POLIO REPEVAX Vaccine (dtap/ipv) Or Adsorbed DIPHTHERIA/TETANUS/acellular
More informationGG&C PGD ref no: 2018/1603 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2018/1603 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Active immunisation
More informationHEPATITIS A + TYPHOID VACCINE
GG&C PGD ref no: 2017/1522 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Indicated for active immunisation
More informationDocument Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml
Title Document Details Patient Group Direction (PGD) Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml Trust Ref No 1445-36348 Local Ref (optional) Main points the document The treatment of
More informationPatient Group Direction Hepatitis A vaccine Version: Hepatitis A 2015 Start Date: 1 st July 2015 Expiry Date:30 th June 2018
Patient Group Direction Hepatitis A vaccine Version: Hepatitis A 2015 Start 1 st July 2015 Expiry 30 th June 2018 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS: BLACKPOOL
More informationCLINICAL CONTENT OF PATIENT GROUP DIRECTION FOR PNEUMOCOCCAL CONJUGATE VACCINE (Prevenar 13 )
Patient Group Direction for Pneumococcal Conjugate Vaccine (Prevenar 13 ) Version: PNEUMOCOCCAL CONJUGATE 2014.1 Start 1 st February 2014 Expiry 31 st January 2017 THIS PATIENT GROUP DIRECTION HAS BEEN
More informationClinical Condition Indication:
Patient Group Direction ( for Health Care GG&C PGD ref no: 2018/1611 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition
More informationpatient group direction
REVAXIS v01 1/12 REVAXIS (DIPHTHERIA, TETANUS AND POLIOMYELITIS (INACTIVATED) VACCINE (ADSORBED, REDUCED ANTIGEN(S) CONTENT)) PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic
More informationPatient Group Direction For the supply and administration of
Patient Group Direction For the supply and administration of HAEMOPHILUS INFLUENZAE TYPE B AND MENINGOCOCCAL C CONJUGATE VACCINE (HIB-MenC) MENITORIX Vaccine By Registered Nurse/Midwife/Health Visitor
More informationGG&C PGD ref no: 2017/1427 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2017/1427 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Active immunisation against rotavirus.
More informationPatient Group Direction for Combined Hepatitis A & B vaccine Version: Hep A + B Start Date: 1 st January 2014 Expiry Date: 31 st December 2015
Patient Group Direction for Combined Hepatitis A & B vaccine Version: Hep A + B 2014.1 Start 1 st January 2014 Expiry 31 st December 2015 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS:
More informationPatient Group Direction for Varicella vaccine Version: Varicella Start Date: 1 st May 2014 Expiry Date: 30 th April 2017
Patient Group Direction for Varicella vaccine Version: Varicella 2014.1 Start Date: 1 st May 2014 Expiry Date: 30 th April 2017 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS:
More informationAdministration of Hepatitis A and B Vaccine
PRACTICE: Ref No: PGD/ONEL/2011/006 Valid from December 2011 Valid to December 2013 Supersedes PGD: Any previous PGD used to administer Twinrix Adult and Paediatric vaccine Professional groups covered
More informationPatient Group Direction No. VI 17. Kathy Wakefield/Lisa Murray. General Practices & TRFT. Relevant Clinical Lead
T i:1 Patient Group Direction (PGD) for The Administration of Meningococcal Group C Conjugate Vaccine (Meningitec /NeisVac-C /Menjugate Kit ) by Registered Nurses employed or commissioned by NHS Rotherham
More informationThis Patient Group Direction has been developed/reviewed in accordance with NICE guidance by:- Position of Signatory Name Signed Date
Patient Group Direction Administration of Hepatitis B Vaccine By Registered Nurses employed by GP Practices within Stafford & Surrounds Clinical Commissioning Group This Patient Group Direction has been
More informationPatient Group Direction for HEPATITIS A AND TYPHOID VACCINE. Version No.: 4/2014. Hitesh Patel Pharmaceutical Adviser, NHS Telford & Wrekin CCG
Document Title: Patient Group Direction for HEPATITIS A AND TYPHOID VACCINE PCT Doc Ref.: Local Doc Ref.: PGD Version No.: 4/2014 Author/Owner: File Reference: Document Overseeing Group: Hitesh Patel Pharmaceutical
More informationTHIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS:
Patient Group Direction for Pneumococcal polysaccharide vaccine VERSION: PNEUMOCOCCAL POLY-2013.1 (Pneumovax II ) Start 1 st May 2013 Expiry 30 th April 2015 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED
More informationPatient Group Direction for Measles, Mumps & Rubella Vaccine. PGD Version No.: 7/2013.
Document Title: Patient Group Direction for Measles, Mumps & Rubella Vaccine Area Team Doc Ref.: PGD Version No.: 7/2013 Doc Ref.: http://www.england.nhs.uk/mids-east/ss-at/immunisations/ Author: Owner:
More informationChange history Version number Change details Date Updated for National ACWY programme to be implemented August June 2015.
Patient Group Direction for Conjugate Meningococcal ACWY vaccine Version: MEN ACWY CONJUGATE 2015.1 Start 1 st August 2015 Expiry 31 st July 2018 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING
More informationDocument Details. Patient Group Direction
Document Details Title Patient Group Direction (PGD) Salbutamol Aerosol Inhaler and salbutamol Nebulised Solution Trust Ref No 1569-34313 Local Ref (optional) Main points the document Treatment of acute
More informationGG&C PGD ref no: 2018/1589 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2018/1589 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Individuals requiring active immunisation
More informationClinician Responsible for Training and Review: Emergency Department Consultant
Patient Group Direction for the supply and/or administration of Paracetamol Oral Suspension 250mg/5ml (Paracetamol paediatric suspension) to children receiving treatment from NHS Borders services. This
More informationVersion Number: 02. Patient Group Direction drawn up by: Jayne Bruce - Deputy Director of Nursing Standards and Safety Sussex
PATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF INFLUENZA VACCINE BY REGISTERED NURSES (PEER VACCINATORS) TO STAFF WORKING FOR SUSSEX PARTNERSHIP NHS FOUNDATION TRUST Version Number: 02 Patient
More informationCONJUGATE MENINGOCOCCAL (ACWY) VACCINE
Cumbria & Lancashire Vaccine PGD Group ADVISORY INFORMATION FOR USE WITH PATIENT SPECIFIC DIRECTION OR INDIVIDUAL PRESCRIPTION SIGNED BY GP OR NON-MEDICAL PRESCRIBER. CONJUGATE MENINGOCOCCAL (ACWY) VACCINE
More informationPatient Group Direction for Varicella vaccine Version: Varicella Start Date: 1 st April 2016 Expiry Date: 31 st March 2019
Patient Group Direction for Varicella vaccine Version: Varicella 2016.1 Start Date: 1 st April 2016 Expiry Date: 31 st March 2019 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS:
More informationPATIENT GROUP DIRECTION PROCEDURE
PATIENT GROUP DIRECTION PROCEDURE Date approved 2 October 2015 Version 3 Approved by Yvette Oade, Chief Medical Officer Procedure Lead Clinical Governance Lead - Medicines Management Procedure Author Karen
More informationPatient Group Direction
This Patient Group Direction (PGD) must only be used by registered health professionals who have been named and authorised by their organisation to practice under it. The most recent and in date final
More informationAdministration of shingles (herpes zoster) vaccine (live) Zostavax. Version 7.0 updated for programme from September 2017 to August 2018
Patient Group Direction template Administration of shingles (herpes zoster) vaccine (live) Zostavax Version 7.0 updated for programme from September 2017 to August 2018 This specimen Patient Group Direction
More informationPatient Group Direction for Rotavirus vaccine Version: ROTAVIRUS (Rotarix ) Start Date: 1 st July 2013 Expiry Date:30 th June 2015
Patient Group Direction for Rotavirus vaccine Version: ROTAVIRUS-2013. 1 (Rotarix ) Start 1 st July 2013 Expiry 30 th June 2015 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS:
More informationClinician Responsible for Training and Review: Emergency Department Consultant
Patient Group Direction for the Supply of Salbutamol Inhaler to patients receiving treatment from NHS Borders Emergency Department/Out of Hours/Minor Injury Units This document authorises the supply or
More informationPatient Group Direction For the supply and administration of
Patient Group Direction For the supply and administration of Adsorbed low dose DIPHTHERIA/TETANUS/acellular PERTUSSIS/ inactivated POLIO REPEVAX Vaccine (dtap/ipv) By Registered Nurse/Midwife/Health Visitor
More informationPATIENT GROUP DIRECTION (PGD)
PATIENT GROUP DIRECTION (PGD) SUPPLY OF NALOXONE HYDROCHLORIDE INJECTION BY REGISTERED NURSES TO CLIENTS BEING RELEASED FROM HMP FORD Version Number: 01HMP Patient Group Direction originally drawn up by:
More informationPatient Group Direction For The Administration Of Rotavirus Vaccine Rotarix By Nurses, Midwives and Health Visitors Working Within.
NHS Grampian Patient Group Direction For The Administration Of Rotavirus Vaccine Rotarix By Nurses, Midwives and Health Visitors Working Within NHS Grampian Lead Author: Consultation Group: Approver: Medicines
More informationPatient Group Direction for the Administration of Human Papilloma Virus (HPV) Vaccine (Gardasil and Cervarix )
Patient Group Direction for the Administration of Human Papilloma Virus (HPV) Vaccine (Gardasil and Cervarix ) This PGD must be read in conjunction with the core PGD (Reference: NHSE(LR)/PGD/Core PGD for
More informationDirection Number: - NECSAT 2014/014
Patient Group Direction (PGD) for the Administration of COMBINED DIPHTHERIA, TETANUS, ACELLULAR PERTUSSIS AND INACTIVATED POLIOMYELITIS VACCINE (Repevax / Infanrix IPV ) by Registered Professionals to
More informationPatient Group Direction For the supply and administration of
Patient Group Direction For the supply and administration of Vi Capsular Polysaccharide Typhoid Vaccine(Ty2) Brands TYPHERIX Vaccine TYPHIM Vi Vaccine To adults and/or children over 2 years of age Or Oral
More informationPRODUCT CIRCULAR. GARDASIL [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine]
PRODUCT CIRCULAR [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine] I. THERAPEUTIC CLASS GARDASIL is a recombinant, quadrivalent vaccine that protects against Human Papillomavirus
More informationNHS public health functions agreement Service specification No.32 Human papillomavirus immunisation programme for men who have sex with men
NHS public health functions agreement 2018-19 Service specification No.32 Human papillomavirus immunisation programme for men who have sex with men (HPV-MSM) 1 NHS public health functions agreement 2018-19
More informationPATIENT GROUP DIRECTION
Midlands and East (Central Midlands) PATIENT GROUP DIRECTION NHS England Midlands and East (Central Midlands) Patient Group Direction for the administration of Bexsero suspension for injection (Meningococcal
More informationDirection Number: - NECSAT 2014/007
Patient Group Direction (PGD) for the Administration of COMBINED LOW DOSE DIPTHERIA, TETANUS AND INACTIVATED POLIO VACCINE (Td/IPV Revaxis ) by Registered Professionals to Individuals Accessing NHS Services
More informationPatient Group Directions (PGDs)
Patient Group Directions (PGDs) Document level: Trustwide (TW) Code: MP2 Issue number: 4 Lead executive Authors details Type of document Target audience Document purpose Medical Director Senior Clinical
More informationPATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF COMBINED HEPATITIS A&B VACCINE
PATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF COMBINED HEPATITIS A&B VACCINE Valid from: June 2016 Review date: May 2018 Expiry date: June 2018 Developed by Name Job Title Signature Date Senior
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER
PACKAGE LEAFLET: INFORMATION FOR THE USER Gardasil, suspension for injection in a pre-filled syringe Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed) Read all of this leaflet
More informationDirection Number: - NECSAT 2015/001
Patient Group Direction (PGD) for the Administration of HEPATITIS A VACCINES by Registered Professionals to Individuals Accessing NHS Services in Cumbria and North East Sub Region (NHS England North) YOU
More informationDirection Number: - NECSAT 2014/017
Patient Group Direction (PGD) for the Administration of HEPATITIS B VACCINE For Infants by Registered Professionals to Individuals Accessing NHS Services in Durham, Darlington, Tees (DDT) and Cumbria,
More informationPGD Version No.: 3/
Document Title: Patient Group Direction for Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) - Prevenar 13 ( ) Area Team Doc Ref.: PGD Version No.: 3/2014 NHS Doc Ref.: Author: Owner:
More informationClinical Condition Indication:
GG&C PGD ref no: 2016/1366 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Active immunisation against disease
More informationPatient Group Direction
Patient Group Direction For the supply and administration of PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT) PNEUMOVAX II Vaccine By Registered Nurse/Midwife/Health Visitor To Adults and children over
More informationJacqui Seaton, Head of Medicines Management/Hitesh Patel, Pharmaceutical Adviser, NHS Telford & Wrekin CCG
Document Title: Patient Group Direction for HEPATITIS B VACCINE CCG Doc Ref.: Local Doc Ref.: Author/s: Owner: File Reference: Document Overseeing Group: PGD Version No.: 1/2016 Jacqui Seaton, Head of
More informationPATIENT GROUP DIRECTION (PGD) Supply of potassium iodide 65mg tablets to adults and children exposed to, or at risk of exposure to radioactive iodine
PHE publications gateway number: PATIENT GROUP DIRECTION (PGD) Supply of potassium iodide 65mg tablets to adults and children exposed to, or at risk of exposure to radioactive iodine For the supply of
More informationAdministration of Tuberculin Purified Protein Derivative (PPD) 2TU per 0.1ml to patients attending BCG clinics with identified TB at risk factors.
Administration of Tuberculin Purified Protein Derivative (PPD) 2TU per 0.1ml to patients attending BCG clinics with identified TB at risk factors. Special notes PPD is an unlicensed medicine and therefore
More informationPATIENT GROUP DIRECTION
Midlands and East (Central Midlands) PATIENT GROUP DIRECTION NHS England Midlands and East (Central Midlands): for use in South Midlands and Hertfordshire Patient Group Direction for the administration
More informationContinence PGD transdermal oxybutynin Kentera patch 36mg
Continence PGD transdermal oxybutynin Kentera patch 36mg Patient group direction for the supply of transdermal oxybutynin Kentera patch 36mg to patients suffering from urinary frequency, urgency or incontinence
More informationThe national human papillomavirus (HPV) vaccination programme - the move to two-dose schedule
The national human papillomavirus (HPV) vaccination programme - the move to two-dose schedule An update for registered healthcare practitioners August 2014 Quality Education for a Healthier Scotland 1
More informationDeveloped By Name Signature Date
Patient Group Direction 2156 version 2.0 Administration of Ipratropium 250mcg/ml Nebuliser Solution in Acute Asthma by Registered Practitioners employed by Torbay and South Devon NHS Foundation Date of
More informationContinuous Professional Education Programme for Registered Nurses and Midwives to Administer Gardasil Vaccine
Continuous Professional Education Programme for Registered Nurses and Midwives to Administer Gardasil Vaccine Under the Medicine Protocol to Girls in Second Level Schools (or equivalent) through a Schools
More informationExpiry Date: September 2009 Template Version: Page 1 of 7
GG&C PGD ref 2007/467 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Exclusion criteria:
More informationDeveloped By Name Signature Date
Patient Group Direction 2155 version 2.0 Administration / Supply of Inhaled Salbutamol in Asthma by Registered Practitioners employed by Torbay and South Devon NHS Foundation Trust Date of Introduction:
More informationDocument Title: Patient Group Direction for Adrenaline (Epinephrine) 1:1000. Version No.: 07/2014. Medicines Management Committee
Document Title: Patient Group Direction for Adrenaline (Epinephrine) 1:1000 PCT Doc Ref.: Local Doc Ref.: PGD Version No.: 07/2014 Author/Owner: File Reference: Document Overseeing Group: Jacqui Seaton,
More informationPolicy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical Commissioning Group
BEFORE USING THIS POLICY ALWAYS ENSURE YOU ARE USING THE MOST UP TO DATE VERSION Policy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical
More informationPatient Group Direction For The Pre-Exposure Prophylactic Administration Of Rabies Vaccine By Nurses And Pharmacists Working Within NHS Grampian
NHS Grampian Patient Group Direction For The Pre-Exposure Prophylactic Administration Of Rabies Vaccine By Nurses And Pharmacists Working Within NHS Grampian Lead Author: Consultation Group: Approver:
More informationEnhanced Service Specification. Childhood seasonal influenza vaccination programme 2018/19
Enhanced Service Specification Childhood seasonal influenza vaccination programme 2018/19 Contents Childhood seasonal influenza vaccination programme... 1 Contents... 4 1 Introduction... 5 2 Background...
More informationEnhanced Service Specification. Childhood seasonal influenza vaccination programme 2017/18
Enhanced Service Specification Childhood seasonal influenza vaccination programme 2017/18 2 Enhanced Service Specification Childhood seasonal influenza vaccination programme Version number: 1 First published:
More informationNATIONAL PATIENT GROUP DIRECTION FOR SUPPLY OF PARACETAMOL ORAL SUSPENSION
NATIONAL PATIENT GROUP DIRECTION FOR SUPPLY OF PARACETAMOL ORAL SUSPENSION 120 mg/5ml FOR PREVENTION OF POST IMMUNISATION FEVER FOLLOWING ADMINISTRATION OF MENINGOCOCCAL GROUP B VACCINE (BEXSERO ) BY AUTHORISED
More informationDirection Number: - NECSAT 2014/003
Patient Group Direction (PGD) for the Administration of MEASLES, MUMPS AND RUBELLA VACCINE (MMR) by Registered Professionals to Individuals Accessing NHS Services in Durham, Darlington, Tees (DDT) and
More informationPATIENT GROUP DIRECTION. Pandemrix (GSK brand) Pandemic influenza vaccine (H1N1)v (Split virion, inactivated, adjuvanted)
PATIENT GROUP DIRECTION Supply / Administration of: Pandemrix (GSK brand) Pandemic influenza vaccine (H1N1)v (Split virion, inactivated, adjuvanted) By: Nurses, Health Visitors and Pharmacists In: General
More informationPALIPERIDONE LONG ACTING INJECTION PRESCRIBING GUIDELINE. Chief Pharmacist. Chief Pharmacist
REFERENCE NUMBER: PALIPERIDONE LONG ACTING INJECTION PRESCRIBING GUIDELINE AREA: NAME OF RESPONSIBLE COMMITTEE / INDIVIDUAL NAME OF ORIGINATOR / AUTHOR Trust-wide Chief Pharmacist Chief Pharmacist DATE
More informationSAMPLE. This direction was authorised on 4/5/2007. The direction will be reviewed by 4/5/2009
Patient Group Direction for the Supply and Administration of Flumazenil 100microgram Injection To Patients requiring reversal of oversedation due to midazolam in association withendoscopy attending Endoscopy
More informationPATIENT GROUP DIRECTION
Midlands and East (Central Midlands) PATIENT GROUP DIRECTION NHS England Midlands and East (Central Midlands): for use in South Midlands and Hertfordshire Patient Group Direction for the administration
More informationExpiry Date: July 2009 Template Version: Page 1 of 7
Salbutamol nebules YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT NPGD2007/355 (supersedes 2004/177) Clinical Condition Indication: Inclusion
More informationPatient Group Direction for the supply and/or administration of Ibuprofen 400mg tablets to patients attending NHS Borders services
Patient Group Direction for the supply and/or administration of Ibuprofen 400mg tablets to patients attending NHS Borders services This document authorises the supply and/or administration of Ibuprofen
More informationIMOVAX POLIO POLIOMYELITIS VACCINE (INACTIVATED) Suspension for injection in prefilled syringe
IMOVAX POLIO POLIOMYELITIS VACCINE (INACTIVATED) Suspension for injection in prefilled syringe Read all of this leaflet carefully before you are vaccinated or before you have your child vaccinated. Keep
More informationPrescription only medicines (POMs)
Prescription only medicines (POMs) 2017 Learning objectives Explain the legal framework with which registered health care professionals can administer prescription only medicines Define the role and limitations
More informationSALBUTAMOL INHALER PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline
SALBUTAMOL INHALER PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline 1.1. This Patient Group Direction (PGD) applies to all nursing and clinical staff in the Child Health Department
More informationPATIENT GROUP DIRECTION (PGD)
PHE publications gateway number: 2017015 PATIENT GROUP DIRECTION (PGD) Administration of Hepatitis B recombinant DNA (rdna) vaccine (adsorbed) to individuals who are 15 years of age or over and are on
More informationPATIENT GROUP DIRECTION (PGD) FOR THE SUPPLY OR ADMINISTRATION OF LEVONORGESTREL 1500 MICROGRAM TABLET (e.g LEVONELLE 1500 ) PGD
This Patient Group Direction () must only be used by registered pharmacists who have been named and authorized by their organization to practice under it. The most recent and in date final signed version
More informationCALDERDALE PRIMARY CARE TRUST
CALDERDALE PRIMARY CARE TRUST PATIENT GROUP DIRECTION FOR THE SUPPLY AND ADMINISTRATION OF MEDICINES BY NON- MEDICAL PERSONNEL Progestogen-only emergency contraception for use in Community Pharmacies APPROVED
More information